Given the relevance of the GPR54/kisspeptin system in different pathologies (from cancer to type 2 diabetes), we envisage that peptide 7 will enable new real‐time mechanistic studies and accelerate the development of GPR54‐targeted therapeutics. The gene discussed is KISS1R; the disease is type 2 diabetes mellitus.